Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.16
Bid: 4.14
Ask: 4.78
Change: -0.25 (-5.67%)
Spread: 0.64 (15.459%)
Open: 4.16
High: 4.16
Low: 4.16
Prev. Close: 4.41
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PHC and Arysta LifeScience sign license agreement

25 Apr 2013 07:00

RNS Number : 1706D
Plant Health Care PLC
25 April 2013
 



 

25 April 2013

 

 

PLANT HEALTH CARE PLC

 

 

Plant Health Care signs license agreement with Arysta LifeScience

 

Plant Health Care (AIM / CISX: PHC.L) and Arysta LifeScience Corporation are pleased to announce that they have signed a Product Development and License Agreement for use of Plant Health Care's proprietary Harpin alpha beta technology. Commercial terms were not disclosed.

 

Arysta LifeScience will develop and commercialize Harpin alpha beta in several crops and markets in combination with a number of Arysta LifeScience-brand foliar products. Sales of the first combination product are anticipated in the USA following registration in time for the 2014 use season.

 

Research demonstrates that use of Harpin in combination with triazoles can make a significant contribution to the management of resistance to the strobilurin family of chemistry. The international Crop Protection Chemical Stewardship Organization's Fungicide Resistance Action Committee (FRAC) has identified strobilurin fungicides as being at "high risk" for the development of disease resistance.

 

Paul Schmidt, CEO of Plant Health Care, commented: "We are delighted to enter into this relationship with Arysta LifeScience which promises a number of new products that will use Harpin alpha beta technology to offer improved plant health benefits and superior disease control. This relationship marks a significant step forward for Plant Health Care, and for United States farmers who will benefit from improved yields."

 

Wayne Hewett, President and CEO of Arysta LifeScience, commented: "Arysta LifeScience is excited to access the Harpin alpha beta technology for use in combination with Arysta LifeScience's value-added product portfolio. The technology has been validated in the United States corn and soybean market and Arysta LifeScience is focused on launching new products in the United States market in 2014 as well as developing the concept in a number of crops and countries."

 

- ENDS-

 

 

About Plant Health Care plc: Plant Health Care plc ("Plant Health Care") is a leading provider of novel patent protected biological products to the global agriculture markets. The Company's ordinary shares have been quoted on the AIM Market of the London Stock Exchange since July 2004 and listed on the Official List of the Channel Islands Stock Exchange ("CISX") since February 2010 (ticker symbol/mnemonic: PHC).

 

 

About Arysta LifeScience Corporation

Headquartered in Tokyo, Japan, Arysta LifeScience is one of the world's largest privately held crop protection and life science companies with 2012 revenues of JPY131.7 billion (US$1.6 billion). An entrepreneurial provider of crop protection and life science products in more than 125 countries worldwide, Arysta LifeScience specializes in marketing and distribution of respected crop protection brands and life science products that meet the needs of our global partners. More information on the company is available at: www.arystalifescience.com.

 

Further information is available at: www.planthealthcare.com or please contact:

 

Plant Health Care plc

Paul Schmidt, Chief Executive Officer

Tel: +1-412-826-5488

Stephen Weaver, Finance Director

Tel: +1-412-826-5488

Nomura Code Securities

Tel: +44 (0) 20 7776 1200

Clare Terlouw / Chris Golden

Powerscourt

Tel: +44 (0) 20 7250 1446

Paul Durman / Nick Dibden / Sophie Moate

Arysta LifeScience Corporation

Linda Frerichs, Global Communications Manager

Tel: +1-919-678-4948

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBLGDSISDBGXS
Date   Source Headline
8th May 20247:00 amRNSTrading Update
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.